FX.co ★ Emergent BioSolutions Names Simon Lowry Chief Medical Officer

Emergent BioSolutions Inc. (EBS) has announced significant leadership changes. Starting November 18, Simon Lowry will step into the role of Chief Medical Officer and Head of Research and Development. Lowry previously held the position of Chief Executive Officer at Mysthera Therapeutics AG. In addition, the company has elevated Jessica Perl to the position of General Counsel and Corporate Secretary. As of the pre-market session, Emergent's stock is trading at $9.01, reflecting a decrease of 1.21 percent on the New York Stock Exchange.